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A B S T R A C T   
Multidrug dosage forms (aka combination dosage forms, polypills, etc.) create value for patients through reduced 
pill burdens and simplified administration to improve adherence to therapy. Enhanced flexibility of multidrug 
dosage forms would provide further opportunities to better match emerging needs for individualized therapy. 
Through modular dosage form concepts, one approach to satisfy these needs is to adapt multidrug dosage forms 
to a wider variety of drugs, each with a variety of doses and release profiles. This study investigates and tech-
nically explores design requirements for extending the capability of modular multidrug dosage form concepts 
towards individualization. This builds on our recent demonstration of independent tailoring of dose and drug 
release, which is here extended towards poorly water-soluble drugs. The challenging design requirement of 
carrying higher drug loads in smaller volumes to accommodate multiple drugs at their clinical dose is here met 
regarding dose and release performance. With a modular concept, we demonstrate high precision (<5% RSD) in 
dose and release performance of individual modules containing felodipine or naproxen in Kollidon VA64 at both 
a wide drug loading range (5% w/w and 50% w/w drug) and a small module size (3.6 mg). In a forward-looking 
design-based discussion, further requirements are addressed, emphasizing that reproducible individual module 
performance is predictive of dosage form performance, provided the modules are designed to act independently. 
Therefore, efforts to incorporate progressively higher drug loads within progressively smaller module volumes 
will be crucial to extend the design window further towards full flexibility of future dosage forms for individ-
ualized multidrug therapy.   
1. Introduction 
Multidrug therapy may either be administered as discrete dosage 
forms or as combination dosage forms (also known as polypills). Poly-
pills have existed in research for over a decade, primarily as fixed-dose 
combinations intended to reduce pill burdens, simplify regimens, and 
promote adherence (Bangalore et al., 2007; Demiri et al., 2018; 
Fernandez-Garcia et al., 2020; Pereira et al., 2020b; Robles-Martinez 
et al., 2019; Rosenthal and Gavras, 2006). However, whilst such 
multidrug dosage forms are advantageous for convenient delivery of 
multidrug therapy, they are not currently designed for individualized 
multidrug therapy. Individualized multidrug therapy in an extensively 
heterogeneous patient population requires multidrug dosage forms to be 
available in sufficiently high variety to facilitate tailoring to individual 
patient needs (Govender et al., 2020b; Srai et al., 2015; Wilson, 2016). 
This includes an increased variety of unit dose strengths (Deng et al., 
2017; Ferrendelli, 2001; Govender et al., 2019, 2020b; Nidanapu et al., 
2016; Pouplin et al., 2014; Wening and Breitkreutz, 2011) and an 
increased variety of drug release profiles (Bhatia et al., 2014; Effinger 
et al., 2019; Govender et al., 2020a; Govender et al., 2020b; Hens et al., 
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2017; Khaled et al., 2015a; McConnell et al., 2008) for each active 
pharmaceutical ingredient (API) in the dosage form. Furthermore, for 
individualized multidrug therapy, tailoring to varying APIs in patients’ 
varying therapeutic regimens is warranted. Although fixed-dose com-
bination products are not typically designed for variety provision or 
enhanced flexibility in each of its components, recently, research on 
flexible-dose products (Fuenmayor et al., 2019; Laukamp et al., 2016; 
Sadia et al., 2018; Wilson, 2016) and products with flexible drug release 
profiles (Genina et al., 2017; Khaled et al., 2015a,b; Pereira et al., 
2020b; Smeets et al., 2020) have emerged. However, interdependencies 
between the size, dose, and drug release remain, typically resulting in 
flexibility in only one product feature at a time. Multifunctional indi-
vidualization, i.e., the simultaneous and independent tailoring of mul-
tiple product features (Govender et al., 2020a; Govender et al., 2020b), 
e.g. dose and drug release within an acceptable dosage form size, is 
crucial to enable holistic individualization without compromising 
handling and swallowability (Drumond and Stegemann, 2020; Meltzer 
et al., 2006; Messina et al., 2015; Page et al., 2016; Ranmal et al., 2016; 
Stegemann et al., 2012). Therefore, enabling multifunctional individu-
alization across a broad variety of APIs is an important goal for multi-
drug dosage forms and the core focus of this study. This serves to enable 
a greater variety of API combinations through interchangeability of each 
API and its respective dose and drug release, when required. To the 
authors’ knowledge, the conditions which enable multifunctional indi-
vidualization across a wide variety of APIs for multidrug dosage forms 
have not yet been elucidated. Specifically, demonstrating opportunities 
for interchangeability between APIs of varying physicochemical char-
acteristics in the multidrug dosage form, whilst individualizing the dose 
and drug release of each constituent API, are few (Pereira et al., 2019; 
Pereira et al., 2020a) and still lack the dose–size independence that is 
critical to multifunctional individualization. 
To address this challenge, we position this study in the context of 
modular multidrug dosage forms with a high degree of modularity (i.e. 
more modules in a product). Non-modular multidrug dosage forms, 
containing a mixture of APIs in a common matrix, rely on compatibility 
between constituent APIs and do not satisfy the requirement for inde-
pendent control of product attributes for individualization. A high de-
gree of product modularity is assumed in this study to extend 
applicability of future multidrug dosage forms to individualized multi-
drug therapy. In reality, the required degree of modularity for individ-
ualization will depend, in part, on the extent of variability in the patient 
population for a particular API and how that variability translates to 
health outcomes when treated with a particular product variant. 
It has been demonstrated previously that enhanced product variety 
can be achieved by reconfigurable assembly of unique functional mod-
ules into a final dosage form of predefined individualized performance 
(Siiskonen et al., 2018; Govender et al., 2020a). A higher degree of 
product modularity theoretically corresponds to a higher product vari-
ety using reconfiguration (Gershenson et al., 1999; Ulrich and Tung, 
1991) and is therefore desirable for individualized multidrug therapy. 
Typical multidrug dosage forms with a low degree of modularity and 
fixed assembly of unique API modules into final dosage forms do not 
support enhanced variety through reconfiguration or multifunctional 
individualization. For example, modular fixed-dose combinations are 
modular only with respect to the APIs but not with respect to each API’s 
dose and drug release (Baumgartner et al., 2020; Fernandez-Garcia 
et al., 2020). 
Current polypill research involves plentiful demonstrations of 
assembled polypills (Acosta-Vélez et al., 2018; Fernandez-Garcia et al., 
2020; Genina et al., 2017; Khaled et al., 2015a; Pereira et al., 2019; 
Pereira et al., 2020a; Robles-Martinez et al., 2019; Sadia et al., 2018). 
Importantly, the performance of assembled modular multidrug dosage 
forms is determined by the performance of the individual modules from 
which the dosage form is constructed, provided the modules are 
designed to act independently to meet the requirements for multifunc-
tional individualization. Nevertheless, scrutinizing individual module 
performance and how it can contribute to extending the applicability of 
multidrug dosage forms towards individualized multidrug therapy is 
inadequately addressed to date. In response, this study focuses on the 
performance of individual modules for future application in assembling 
modular multidrug dosage forms with a high degree of modularity 
(Fig. 1). 
A higher degree of modularity for individualized multidrug therapy 
requires not only progressively smaller modules but reproducible and 
robust dose and release performance at low and high drug loads at these 
small module sizes, for a variety of APIs. This is the key technical 
challenge for enabling individualized multidrug therapy and provides 
the rationale for the study focus on individual module performance 
instead of assembly of modules or fabrication of polypills. This study 
aims to delineate the current design window regarding the applicability 
of flexible combination dosage forms to APIs of varying characteristics, 
with a focus on APIs with poor aqueous solubility formulated as amor-
phous solid dispersions. 
The properties of the APIs, specifically the recrystallization tendency 
and dose: solubility ratio, are hypothesized to influence single-module 
performance, potentially limiting the applicability of multidrug dosage 
forms for individualized multidrug therapy to drugs with a low dose and 
low recrystallization tendency. In this study, this challenge is addressed 
by, firstly, demonstrating the effect of drug loading (5% w/w vs. 50% w/ 
w drug) and recrystallization tendency on the variability in the dose 
fraction and drug release kinetics between individual drug-containing 
modules and, thereafter, elucidating the impact of these findings on 
the feasibility of multidrug dosage forms for individualized multidrug 
therapy for a broad variety of APIs. Compositions, manufacturing pro-
cesses, and test parameters were deliberately selected to isolate the ef-
fect of the API properties of interest in this study. The potential of the 
inherent recrystallization tendency of each API to result in recrystalli-
zation during dissolution, not recrystallization during storage, was 
specifically studied. Translating learnings from model systems to real 
therapeutic solutions will require considerations of added complexity 
from storage conditions and duration (which may influence solid state 
properties and stability), manufacturing and dispensing of individual 
modules at varying length scales, and progression towards more bio-
relevant test conditions. However, for future assembly of modules into 
final dosage forms, the time scales of storage and the conditions under 
which storage may occur are not yet established. Therefore, stability 
testing under varying storage conditions is out of scope in this study. 
2. Materials and methods 
2.1. Materials 
Felodipine (FEL) and naproxen (NAP) were selected as model drugs 
because they span extremes of dose (and dose: solubility ratios) and 
recrystallization tendencies. FEL (MW 384.3 g/mol) was obtained from 
AstraZeneca, Sweden. NAP (MW 230.3 g/mol) was purchased from MP 
Biomedicals, Illkirch, France. VA64 (Kollidon® VA64) was supplied by 
BASF, Ludwigshafen, Germany. Sodium dodecyl sulphate (SDS) and 
hydrochloric acid (HCl, 37%) were purchased from Sigma Aldrich, 
Sweden. FEL is classified as a glass-forming ability (GFA) class 3 drug 
with an inherently lower tendency to recrystallize from amorphous form 
(Alhalaweh et al., 2014; Kawakami, 2019; Konno and Taylor, 2006; 
Panini et al., 2019) and a lower daily dose range (typical adult dose 
range 2.5–10 mg) compared to NAP, which is in GFA class 1 with a 
higher tendency to recrystallize (Alhalaweh et al., 2014; Kawakami, 
2019; Liu et al., 2017) and a higher daily dose range for tablets (typical 
adult daily dose range for NAP tablets ~ 500–1000 mg). This model drug 
selection allowed a common carrier, vinylpyrrolidone-vinyl acetate 
copolymer (VA64) to be used in both systems. 
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2.2. Methods 
2.2.1. Melt extrusion of drug-containing filaments 
Hot melt extrusion (HME) of FEL in VA64 and NAP in VA64 has been 
shown to solubilize higher drug loads than alternative processing 
methods, such as spray drying and cryo-milling, during the formation of 
amorphous solid dispersions (Dedroog et al., 2019; Song et al., 2013). 
Consequently, four compositions were prepared by HME, namely 5% w/ 
w FEL in VA64, 50% w/w FEL in VA64, 5% w/w NAP in VA64, and 50% 
w/w NAP in VA64. They are designated FEL5, FEL50, NAP5, and 
NAP50, respectively, throughout the manuscript. HME was selected to 
obtain amorphous solid dispersions for solubility enhancement of both 
APIs as well as to obtain a homogeneous distribution of the drugs in the 
VA64 through HME’s dispersive and distributive mixing. The upper 
limit for drug load at 50% w/w API was based on the maximum amount 
of drug that could be solubilized in VA64 during HME allowing the 
formulation to remain amorphous in the solid state for subsequent drug 
release testing. The minimum drug load of 5% w/w API represents 
reference formulations, which were required to elucidate the impact of 
drug loading on individual module performance. The selection of VA64 
was based on its ability to solubilize both drugs at the drug loading range 
of interest in the solid state (Lu et al., 2019; Sarpal et al., 2019), thereby 
allowing discrimination of the role of the API on dose and release per-
formance in modular dosage forms. For each composition, VA64 pow-
der, together with either FEL powder or NAP powder, was weighed in a 
weigh boat in an approximately 5 g batch size and mixed with a spatula 
until homogeneous upon visual inspection. Physical mixtures were fed 
via a hopper into the barrel of a 5 mL capacity Xplore micro compounder 
(Xplore, The Netherlands), affixed with conical mixing screws and a 
circular die, 1.5 mm in diameter. Both FEL-containing and NAP- 
containing formulations were fed into a barrel set at 100 ◦C. This was 
below the glass transition temperature (Tg) of pure VA64 which pre-
vented sticking and bridging of the powdered polymer in the hopper. 
After complete feeding (<2 min), the barrel temperature was increased 
to 150 ◦C for FEL-containing formulations and 160 ◦C for NAP- 
containing formulations, at which temperatures the mixtures were 
recirculated for 10 min to aid homogenization prior to extrusion through 
the die to obtain cylindrical filaments, which were allowed to cool at 
room temperature. These processing temperatures were above the 
melting temperatures (Tm) of the pure drugs and below the degradation 
temperatures of all components (229 ◦C for FEL, 236 ◦C for NAP, and 
292 ◦C for VA64), as determined by the thermogravimetric analysis 
(TGA) method described in 2.2.3. Ejection required a reduction in barrel 
temperature to 115 ◦C for the formulations containing 50% w/w drug to 
allow an increase in ejection force. A constant screw speed of 50 rpm was 
maintained throughout feeding, recirculation, and ejection. Filaments 
were stored for 1–3 days post-extrusion in sealed plastic bags at room 
temperature prior to further processing. The physical stability of these 
model systems under varying conditions and durations has been studied 
previously (Lehmkemper et al., 2018, Song, et al., 2013). 
2.2.2. Sectioning of melt-extruded filaments into target module size 
Melt-extruded filaments were cut into sections with a blade on the 
same day as the drug release testing was to be conducted. These filament 
sections represent the modules that were used in in vitro drug release 
testing immediately after sectioning. The nominal module size for the 
standard-size (small) modules was set at 3.5 mg. This was based on the 
minimum module size that could be reproducibly generated from the 
extruded filament across formulations and satisfy the volumetric con-
straints of the drug release testing method. Larger modules of 7 mg were 
also prepared for some of the release experiments described below. All 
modules were obtained from different regions along the length of the 
extruded filament. Individual modules from FEL5, FEL50, NAP5, and 
NAP50 were weighed in a Mettler MT5 analytical balance (Mettler 
Toledo, Greifensee, Zurich, Switzerland) and module dimensions were 
measured using a digital caliper. 
2.2.3. Thermal characterization 
To determine the onset of thermal degradation of raw materials 
(Tdeg), TGA was performed on FEL, NAP, and VA64 powders using a 
TGA/DSC 3 + STARe system instrument (Mettler Toledo, Switzerland). 
These powders were weighed in open 70 µL aluminium crucibles using 
the built-in TGA balance and heated from 30 ◦C to 500 ◦C at 10 ◦C/min 
under a nitrogen atmosphere with a 50 mL/min flow rate. Tdeg was re-
ported from the weight vs. temperature curve as the first observed mass 
loss from the initial baseline in the absence of water loss. In order to 
facilitate comparison between drugs with different recrystallization 
tendencies during dissolution, differential scanning calorimetry (DSC) in 
a DSC 2 STARe system instrument (Mettler Toledo, Switzerland) was 
first performed to ensure an absence of crystallinity in melt-extruded 
formulations in the solid state. Melt-extruded filaments and raw mate-
rials were weighed separately in 40 µL aluminium crucibles and sealed 
with aluminium lids with a pinhole. The instrument was run in a heat- 
cool-heat cycle at 10 ◦C/min under a 100 mL/min nitrogen atmo-
sphere for all samples (heating from 25 ◦C to 220 ◦C, cooling to − 50 ◦C 
and reheating to 220 ◦C for FEL-containing samples and heating from 
25 ◦C to 200 ◦C, cooling to − 50 ◦C and reheating to 200 ◦C for NAP- 
containing samples). STARe software (version 16.00b, Mettler Toledo, 
Greifensee, Zurich, Switzerland) was used for instrument control and 
thermogram analysis. DSC was run on the same day as each drug release 
test to ensure the absence of crystallinity in the samples in the solid state 
prior to commencement of the drug release test. Tg was reported as the 
midpoint of the Tg range and Tm, if present, was reported as the peak of 
the melting endotherm. 
2.2.4. Wide angle X-ray scattering (WAXS) 
A non-destructive analytical method, WAXS, was also used to 
confirm the absence of crystallinity in the melt-extruded filaments from 
which the modules for drug release testing were obtained. The filaments 
were analyzed intact through the bulk of the sample perpendicular to 
the direction of extrusion using a Mat: Nordic X-Ray scattering instru-
ment (SAXSLAB, Copenhagen, Denmark) equipped with a high bril-
liance Rigaku 003 X-Ray micro-focus Cu-radiation source (Rigaku 
Fig. 1. The focus of this study on individual module dose and release performance for future application as assembled polypills for individualized multidrug therapy 
(exemplified in the figure). 
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Innovative Technologies Inc., Michigan, United States) and a Pilatus 
300 K detector (Dectris, Baden-Daettwil, Switzerland). Samples were 
analyzed in a vacuum at room temperature with an exposure time of 
300 s, beam size of 0.9 mm, and a sample-to-detector distance of 134 
mm. The scattering data was collected in the form of a 2D diffraction 
pattern and the 2D detector intensity was then radially integrated to 
produce the scattering curve. Ganesha Interactive Control Center (GICC) 
software (SAXSLAB, Copenhagen, Denmark) was used for instrument 
operation and the graphical user interface SAXSGUI (Rigaku Innovative 
Technologies Inc., Michigan, United States and JJ X-Ray Systems ApS., 
Hoersholm, Denmark) was used for integration from the 2D detector 
scattering patterns to the resulting 1D curves. 
2.2.5. In vitro drug release and drug content homogeneity 
In vitro drug release testing was performed on all formulations. 
Unlike FEL, NAP has a pH-dependent solubility, therefore all experi-
ments were conducted in 0.1 M HCl (pH = 1.4) containing 50 mM SDS, 
where NAP has poor aqueous solubility. For comparison purposes, 
selected samples were also evaluated without SDS under non-sink con-
ditions. Sink indices were calculated and reported as 
SI = Cs/(Dose/V)
where Cs is the equilibrium solubility of the drug at 37 ◦C in the disso-
lution medium and V is the volume of the dissolution medium (Sun et al., 
2016). Volumes of interest for the entire study spanned two orders of 
magnitude between 7 mL and 900 mL to account for the varying dose: 
solubility ratios of FEL and NAP and provide an equivalent sink index 
under non-sink conditions of ~ 0.5 calculated as above. Consequently, 
for volumes 100 mL and higher (i.e. FEL5 and FEL50), the test was 
carried out in a USP 2 dissolution apparatus (Varian 705-DS, Agilent 
Technologies, California, USA) and for samples less than 100 mL (NAP5 
and NAP50), a modified USP 1 setup was used, which replaced the large- 
capacity vessels with small 50 mL or 100 mL glass beakers, each sus-
pended at an equivalent height from the bottom of the rotating basket. 
All beakers used in a specific test were identical in diameter. In the case 
of the USP 2 setup, the samples were suspended in the medium and 
immediately sank to the bottom of the vessel, whereas for the modified 
USP 1 setup, the samples were housed in the rotating basket. Dissolution 
apparatuses were operated at 37 ± 1 ◦C, 50 rpm. Vessel temperature was 
verified before sample insertion, i.e., before the commencement of each 
test. At predefined timepoints, 1 mL aliquots of media were withdrawn 
with fresh media replacement. Withdrawn aliquots were analyzed by 
ultraviolent (UV) absorbance spectroscopy using a Cary60 UV–Vis 
spectrophotometer (Agilent Technologies, Inc., CA, USA). Cary WinUV 
scan application software (version 5.0.0.999, Agilent Technologies, Inc., 
CA, USA) was used for instrument operation and acquisition of spectra. 
All sample solutions were scanned at 4800 nm/min from 800 nm to 290 
nm for FEL-containing sample solutions and 800 nm to 200 nm for NAP- 
containing sample solutions. Lower wavelengths were excluded for FEL 
due to potential photodegradation of FEL at these wavelengths (De Luca 
et al., 2019; Pizarro et al., 2007). FEL and NAP concentrations were 
quantified from sample absorbance at 365 nm and 273 nm, respectively 
and from a calibration curve of drug-containing standards (concentra-
tion range 1–10 µg/mL). Linearity was confirmed over this concentra-
tion range. Absorbance readings corresponding to greater than or equal 
to the limit of quantification (signal: noise > 10) were reported. Drug 
content was quantified from the 100% release timepoint for modules 
obtained from different sections along the length of the extruded fila-
ment and compared to the theoretical individual module drug content. 
3. Results 
3.1. Confirmation of absence of crystallinity in the solid State: DSC 
Fig. 2A and 2B show thermal transitions of raw materials (FEL, NAP) 
and melt-extruded filaments (FEL5, FEL50, NAP5, NAP50, and VA64) 
during the first heat cycle. The first heat cycle elucidates the effect of the 
melt extrusion processing conditions on the solid state of the API in the 
resulting melt-extruded filaments. 
Crystalline FEL powder and crystalline NAP powder displayed 
melting endotherms at 150.2 ◦C and 157.4 ◦C, respectively (Tm, 
midpoint), which are in approximate agreement with those reported in 
literature (Chen et al., 2018; Dedroog et al., 2019; Guo et al., 2020; 
Kawakami, 2019; Liu et al., 2017; Lu et al., 2019). The absence of 
endothermic peaks for both FEL5 and FEL50 filaments in the region of 
the pure FEL melting peak (red band in Fig. 2A) confirms an absence of 
crystallinity in these compositions. VA64 is established as a polymer 
with a good ability to solubilize and stabilize FEL in the solid state, 
rationalizing its selection in this study (Song et al., 2013). In fact, pre-
vious studies on melt extruded FEL in VA64 filaments revealed that drug 
loads up to 70% w/w could be achieved in the filaments without crys-
talline phase separation (Lu et al., 2019; Sarpal et al., 2019). Fig. 2B 
shows that NAP5 and NAP50 also exhibited an absence of crystallinity in 
the solid state, analogous to what has been reported previously 
(Dedroog et al., 2019). The small endotherm at ~ 42 ◦C for NAP50 
corresponds to enthalpic relaxation, which is typically observed towards 
the end of the Tg range post-extrusion. Processing both formulations 
above the melting temperature of the APIs during melt extrusion was 
chosen to enable improved solubilization and miscibility of the APIs in 
VA64 (Dedroog et al., 2019; Palazi et al., 2018). Due to the choice of 
polymeric carrier and process conditions, both drugs were able to form 
crystal-free extrudates at 5% w/w and 50% w/w. VA64 displayed a 
broad water loss endotherm during the first heat cycle due to the hy-
groscopicity of the polymer (Maddineni et al., 2015; Song et al., 2013), 
which masked the glass transition temperature. This was corroborated 
as a mass loss during TGA (Appendix A, Figure A1). Consequently, the Tg 
Fig. 2. DSC thermal transitions of (A) FEL and VA64 (red traces), FEL5 and FEL50 (black traces); (B) NAP and VA64 (blue traces), NAP5 and NAP50 (black traces) in 
heat cycle 1, endotherms point upwards. 
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was determined from the second heat cycle at approximately 108 ◦C (Tg, 
midpoint). Since the presence of moisture in melt-extruded filaments 
may hinder accurate reporting of the Tg in the first heat cycle, the reader 
is referred to Appendix A (Figure A2) for Tg determination during the 
second heat cycle. Subsequent release testing relied upon an absence of 
crystallinity in the solid state to isolate recrystallization during disso-
lution as a contributor to variability in drug release kinetics of individual 
modules. Consequently, according to these DSC results, all formulations 
could be used in subsequent drug release testing. 
3.2. Confirmation of absence of crystallinity in the solid state: WAXS 
To corroborate the absence of crystallinity revealed during DSC, a 
second analytical method, WAXS, was used. Pure FEL (Fig. 3A, top trace) 
and pure NAP (Fig. 3B, top trace) showed sharp, intense peaks in the 
WAXS curve, characteristic of crystalline materials. 
In contrast, VA64, FEL5, FEL50, NAP5, and NAP50, showed broad 
peaks distributed over a wide 2θ range, which are characteristically 
ascribed to amorphous materials. Therefore, analogous to the DSC 
findings, WAXS curves confirmed an absence of crystallinity in all 
formulations. 
3.3. Individual module precision in mass, dimensions, and drug content 
To isolate the influence of drug recrystallization tendency during 
dissolution on variability in release kinetics of individual modules, 
precision in individual module mass and dose fraction was critical. 
Fig. 4A and 4B show mean mass and volume, respectively, of small and 
large modules investigated in subsequent drug release testing. The small 
modules were FEL5, FEL50, and NAP50 whereas the large modules were 
NAP5 and NAP50. NAP50 was fabricated as both small and large 
modules to facilitate comparison between small and large module per-
formance at a high drug load. 
Module volumes were calculated based on measured heights and 
diameters of the cylindrical sections cut from melt-extruded filaments. 
Fig. 4A and 4B show that % RSD in mass and volume were within an 
acceptable 5% RSD for modules of both sizes. This reflects not only 
precise sectioning of individual modules but also that consistent extru-
date diameters were obtained from the extruder die. Composition did 
not affect precision at each module size. Fig. 4C shows that drug content 
in individual modules were within 5% RSD of each other for 5% w/w 
and 50% w/w drug loads and within 5% RSD of their target contents. 
This was measured by UV absorbance spectroscopy, where dissolved 
melt-extruded modules displayed the same λmax as standard solutions of 
dissolved pure drug. Since these modules were obtained from different 
sections along the length of the filament, this indicates homogeneity in 
drug distribution in the filaments on a relevant length scale for the 
module sections chosen for subsequent drug release testing. Despite 
NAP50 showing slightly more variability in drug content (within 5% 
RSD) compared to FEL50 (within 1.5% RSD), phase separation was not 
detected as a second Tg during DSC (Fig. 2B) and precision is within 
acceptable limits. With precision in mass, dimensions, and drug content 
established, all modules could be investigated for the contribution of 
FEL and NAP to variability in drug release kinetics. 
3.4. Individual module variability in in vitro drug release kinetics 
In vitro drug release testing was performed in 0.1 M HCl containing 
50 mM SDS to evaluate variability in drug release kinetics (amount of 
drug released at each sampling time point) from individual cylindrical 
modules of predefined size (3.6 mg small modules and 7 mg large 
modules). The NAP systems were evaluated at a larger size (7 mg) than 
the FEL systems (3.6 mg) due to the volumetric constraints of the test 
method, which prevented evaluation of smaller module sizes at low NAP 
loads. Modular dosage forms enable individualization by reconfigurable 
assembly, i.e., combining modules with varying drug loads and/or drug 
release profiles to generate final dosage forms of predictable and pre-
defined performance. To do so, the variability in dose and drug release 
kinetics between modules of the same composition should be as low as 
possible. Consequently, release performance is evaluated by comparison 
of variability in release kinetics between modules of the same compo-
sition in the same test, not comparison between release profiles of 
different modules. The latter would require optimization when trans-
lating model systems to applicability for real target indications. FEL and 
NAP were anticipated to influence variability in release kinetics at an 
individual module level, due to their different recrystallization ten-
dencies. Fig. 5A shows % RSD in the amount of FEL released at each 
sampling time point for 3.6 mg modules for FEL5 (green circles) and 
FEL50 (red circles), with their corresponding drug release profiles in 
Fig. 5B and 5C, respectively. 
For FEL5 and FEL50, drug release from individual modules was 
within 5% RSD (rounded to the nearest whole number) for the duration 
of the experiment, except for the start of the release test (t = 10 min for 
FEL5 and t = 15 min for FEL50). The horizontal dashed lines in Fig. 5A 
Fig. 3. WAXS curves of (A) FEL and VA64 (red traces), FEL5 and FEL50 (black traces); (B) NAP and VA64 (blue traces), NAP5 and NAP50 (black traces).  
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denote acceptable % RSD limits for immediate release dosage forms 
according to the United States Food and Drug Administration (FDA), 
with 20% RSD considered acceptable at early time points and 10% RSD 
considered acceptable for the remaining duration of the drug release test 
(U.S. Food and Drug Administration, 1997). The European Medicines 
Agency stipulates a 10% RSD limit throughout the drug release test for 
prolonged release dosage forms (European Medicines Agency, 2014). In 
this study, we assumed that the modules should satisfy the same re-
quirements for acceptable variability as dosage forms. However, with 
future development of modular dosage forms for individualized therapy, 
clarification of these module specifications is required to determine if 
they maintain, expand, or reduce, the existing design window. The 
horizontal dashed lines in Fig. 5B and 5C denote the expected amount of 
FEL at 100% drug release, revealing that complete drug release was 
achieved under these test conditions for both FEL5 and FEL50, without 
subsequent recrystallization in solution. This was expected since it has 
been shown that the equilibrium solubility of FEL in 1% SDS is 720 µg/ 
mL (Abrahamsson et al., 1994). 1% (50 mM) SDS used in this study 
therefore created sink conditions with respect to crystalline solubility for 
FEL release. In addition to improving the solubility, SDS also improves 
wetting and dissolution rate (Chen et al., 2018; Garcia-Herrero et al., 
2017; Lu et al., 2019). However, upon hydration, crystallization on the 
surface of the FEL50 modules was observed as a change in optical 
properties from transparent to opaque within 2 min of exposure to the 
dissolution medium, which was not observed for the FEL5 modules. 
Amorphous domains, if present in the solid state, were not sufficiently 
large to be detected as a separate Tg with DSC. We therefore surmise that 
this nucleation and crystal growth at the solid–liquid interface occurred 
due to the increased molecular mobility that accompanies a decline in Tg 
upon matrix hydration. Supersaturation at the solid–liquid interface has 
also been previously proposed as a potential explanation for this phe-
nomenon at high drug loads (Edueng, 2019). 
The performance of the FEL modules were then compared to that of 
the NAP modules (Fig. 6). NAP crystalline solubility has been reported as 
29.21 μg/mL in 0.1 M HCl at 37 ◦C (Liu et al., 2017). Addition of 0.5% 
SDS has previously been shown to result in a five-fold increase in NAP 
water solubility (Alizadeh et al., 2018). It has also been shown that NAP 
solubility increases linearly with SDS concentration above the critical 
Fig. 4. (A) Mean module mass (mg) ± SD of n = 10 modules (small) and n = 15 modules (large); (B) mean module volume (mm3) ± SD of n = 10 modules (small) 
and n = 15 modules (large); (C) mean % drug content ± SD of n = 5 modules of varying composition. % RSD is indicated above each data point. Note that the small 
modules include FEL5, FEL50, and NAP50, whereas the large modules include NAP5 and NAP50. 
Fig. 5. (A) Variability in the amount of FEL 
released at each sampling time point from single 
3.6 mg modules of FEL5 (green circles) and 
FEL50 (red circles) and mean amount of FEL 
released (µg) ± SD of n = 5 samples vs. time from 
(B) FEL5 and (C) FEL50. The release medium is 
0.1 M HCl with 50 mM SDS at 37 ◦C. The hori-
zontal dashed lines in Fig. 5A denote FDA % RSD 
limits for immediate release dosage forms and the 
horizontal dashed lines in Fig. 5B and 5C denote 
the expected amount of FEL at 100% drug 
release.   
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micelle concentration at all pHs between pH 2.4 and pH 5.1 (Valero 
et al., 2020). If this approximation is assumed to apply to the test con-
ditions above, a sink index of 2.8 results for NAP release with 50 mM 
SDS. Complete drug release was achieved for NAP5 (Fig. 6B) and the 
small NAP50 modules (Fig. 6C) were confirmed to reach 1817 ± 95 μg 
NAP released at a 24 h measurement point, corresponding to complete 
drug release for NAP50. NAP50 therefore reached T50 at 300 min. 
Similar to FEL50, a change in NAP50 module optical properties also 
occurred from transparent to opaque within 5 min of exposure to the 
dissolution medium. Therefore, recrystallization on the surface of the 
module occurred upon hydration for both FEL50 and NAP50. Fig. 6A, 
shows % RSD in NAP release kinetics at an individual module level for 
NAP5 and NAP50. NAP5 modules exhibited drug release kinetics within 
5% RSD throughout the experiment, however, NAP50 demonstrated 
drug release within 10% RSD, greater variability than the equivalent 
drug load of FEL. Importantly, the dose fraction in each NAP50 module 
was within 5% RSD. To determine whether the 7 mg module size was 
comparable in variability to the 3.6 mg modules sizes used for the FEL 
modules, NAP50 at a 3.6 mg module size was also evaluated. Fig. 6A 
shows that no change in % RSD was observed as a result. FEL50 and 
NAP50 exhibited different drug release rates. Since FEL50 had a greater 
variability in drug release kinetics at the start of the release test, to ac-
count for the varying release rates in FEL50 and NAP50 at a module size 
of 3.6 mg, % RSD in the amount of drug released was compared at T10 
and T40. Fig. 7 shows that FEL50 and NAP50 have comparable vari-
ability at similar earlier timepoints in their release profiles. 
In contrast to what was expected, differences in the inherent 
recrystallization tendencies of each API did not impact variability in 
release kinetics at high drug loads. Altogether, the results under these 
test conditions indicate that low variability in individual module release 
kinetics, required for reconfigurability, is obtained at 5% w/w and 50% 
w/w drug load in individual modules. At a module size of 3.6 mg, this 
translates to a dose fraction of 180 µg at the lower end (at which fine- 
tuning of the dose can occur) and up to 1800 µg at the higher end for 
an individual module. This is a ten-fold range on an individual module 
level which can be harnessed for the purpose of reconfiguration and 
provision of enhanced product variety with reproducible dose and 
release kinetics. Preliminary investigations of drug release were con-
ducted under non-sink conditions with respect to crystalline solubility 
without the addition of SDS to the dissolution medium (Fig. 8). 
Fig. 8A reveals that amorphization of FEL in FEL5 modules provides 
a sufficient solubility advantage to allow supersaturation with respect to 
crystalline solubility. However, this supersaturation was unstable, with 
subsequent crystallization from the dissolved state occurring rapidly 
(Fig. 8A). In contrast, even without SDS, under non-sink conditions, 
supersaturation was achieved and maintained, with complete drug 
release from NAP5 without the need for SDS. Notably, to obtain an 
equivalent sink index for FEL5 and NAP5, volumes of the dissolution 
media were adjusted to remove the influence of their varying crystalline 
solubilities. This resulted in varying concentrations of VA64, dissolved 
from the solid dispersion, of 18 µg/mL VA64 and 500 µg/mL VA64, for 
the FEL5 and NAP5 release tests, respectively. This could play a role in 
improving the solubility of NAP and/or inhibiting crystallization of 
Fig. 6. (A) Variability in the amount of NAP 
released at each sampling time point from single 
7 mg modules of NAP5 (green diamonds), 3.6 mg 
modules of NAP50 (blue empty diamonds) and 7 
mg modules of NAP50 (blue filled diamonds) and 
mean amount of NAP released(µg) ± SD of n = 5 
samples vs. time from (B) NAP5 and (C) NAP50 
(blue empty diamonds are 3.6 mg modules and 
blue filled diamonds are 7 mg modules). The 
release medium is 0.1 M HCl with 50 mM SDS at 
37 ◦C. The horizontal dashed lines in Fig. 6A 
denote % RSD limits for immediate release 
dosage forms according to FDA guidance and the 
horizontal dashed lines in Fig. 6B and 6C denote 
the expected amount of NAP at 100% drug 
release. Variability is smaller than data point 
when not visible.   
Fig. 7. % RSD in the amount of drug released from FEL50 and NAP50 3.6 mg 
modules (n = 5) at T10 and T40. The release medium is 0.1 M HCl with 50 mM 
SDS at 37 ◦C. 
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dissolved NAP from solution. At low drug loads under non-sink condi-
tions, the NAP5 system in this study displays superior performance to 
FEL5 in exploiting the advantage of the amorphous state, despite the 
higher recrystallization tendency of NAP. This emphasizes the impor-
tance of the ability of the selected polymer to serve as a crystallization 
inhibitor both in the solid state and during the dissolution. 
Drug release from FEL50 under non-sink conditions was not detected 
for the duration of the experiment without SDS (Fig. 8B). This is in 
agreement with FEL in VA64 formulations previously investigated 
(Langham et al., 2012) and was attributed to the observed crystallization 
on the surface of FEL50 upon hydration. Although crystallization 
occurred at a different location at high drug loads (in the matrix) 
compared to low drug loads (in solution), it nonetheless necessitated the 
inclusion of SDS for robust performance. Recrystallization on the surface 
of the module also occurred with NAP50, in the absence of SDS, there-
fore dissolved VA64 (originating from the solid dispersion) could 
explain the increased solubility of NAP and detectable drug release from 
NAP50 under non-sink conditions (Fig. 8D). 
These results indicate that, at low drug loads, the inherent recrys-
tallization tendency of the drug can be overcome through polymer se-
lection to solubilize and stabilize the drug both in the solid state and in 
solution (NAP5). Despite drug release from the NAP modules, the lack of 
FEL release from FEL50 under non-sink conditions did not permit 
scrutinizing individual module variability in drug release kinetics using 
test conditions without SDS. Consequently, in this study, individual 
module FEL and NAP variability in release kinetics were obtained from 
tests performed with SDS in the dissolution media. Here, the role of SDS 
was to prevent recrystallization from solution for FEL5 modules at low 
drug loads and to solubilize crystals that evolved on the surface of the 
FEL50 and NAP50 modules at high drug loads. Note that in vivo, the 
presence of bile could aid in solubilizing the drug and achieving rapid 
absorption. In future, simultaneous dissolution–absorption studies 
measuring the absorption potential in relevant gastrointestinal condi-
tions may help elucidate the relationship between solubility, perme-
ability, and dissolution rate for improved clinical applicability. 
Both sets of results, with SDS and without SDS, reveal that drug load 
affects the tendency to recrystallize at the solid–liquid interface upon 
hydration, regardless of the inherent recrystallization tendency of the 
drug. Without optimal polymer selection to inhibit this crystallization 
during storage and throughout dissolution, lower drug loads would be 
needed for robust dose and release performance, which may hinder 
applicability to individualized multidrug therapy. 
4. Discussion 
4.1. Importance of a wide individual module drug loading range for 
individualized multidrug therapy 
It has previously been proposed and demonstrated that, through 
reconfiguration, enhanced product variety can be achieved cost- 
effectively from relatively few module variants in a pharmaceutical 
mass customization context (Siiskonen et al., 2018; Govender et al., 
2020a). Fig. 9 illustrates, through exemplification, the difference in 
product variety achievable through reconfiguration across a narrow 
drug loading range (middle column) compared to a wider drug loading 
range (right column). Reconfiguration relies upon unique modules for 
variety provision therefore the case example with identical modules (left 
column) is provided as a reference for minimum product variety without 
reconfiguration. 
In both cases with unique modules available to construct a dosage 
Fig. 8. Mean amount of drug released (µg) ± SD of n = 5 samples vs. time from (A) FEL5 (3.6 mg module), (B) FEL50 (3.6 mg module), (C) NAP5 (7 mg module), and 
(D) NAP50 (7 mg module). The horizontal dashed lines denote the expected amount of drug at 100% drug release and horizontal solid lines indicate the amount 
solubilized based on the crystalline solubility of each API. Variability is smaller than data point when not visible. 
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form (middle column and right column of Fig. 9), the same number of 
module variants (three in the examples shown) and the same degree of 
modularity (three modules in a product in the examples shown) are 
assumed. The potential number of product variants achievable through 
reconfiguration of unique modules into a dosage form is therefore 
identical (ten product variants in the example shown). However, when 
robust individual module performance for dose and release individual-
ization is only assured within a narrow drug loading range, the actual 
number of product variants could be lower than the potential number of 
product variants. This is due to several combinations yielding the same 
final product variant. The example in Fig. 9 shows that only seven out of 
ten possible product variants are achieved within a narrow drug loading 
range. This scenario also depends on which intermediate drug loads are 
selected for module variants between modules with the lowest and 
highest drug loads. In contrast, the column on the right, which repre-
sents a wide drug loading range, shows that both the actual and po-
tential number of product variants are ten, fully exploiting the potential 
of reconfiguration to enhance product variety. Whether or not the dif-
ferences between each product variant are small enough for fine-tuning 
to individual needs and large enough for clinically relevant variety 
provision for individualized therapy remains to be established. For this, 
the biopharmaceutical performance of these modules under varying 
conditions in vitro, e.g. (Puppolo et al., 2017), and in vivo, pharmaco-
kinetics and pharmacodynamics, and the translation to clinical effect in 
individual patients, need to be evaluated. In the context of individual-
ized multidrug therapy, dose and release modifications both play a role 
in influencing therapeutic outcome based on the individual APIs in the 
patient’s regimen (Alomar, 2014; Moore et al., 2015; Sawada et al., 
2003), based on physiological function (Effinger et al., 2019; Lavan and 
Gallagher, 2016; Stegemann, 2016; Verbeeck and Horsmans, 1998), and 
based on adherence to therapy (Brown and Bussell, 2011; Burkhart and 
Sabate, 2003; Florence and Lee, 2011; Wertheimer et al., 2005), to name 
a few general examples. Although these could be applicable to FEL and 
NAP, for the purpose of this study, FEL and NAP were used as model 
drugs. For future assembly of modules into flexible multidrug dosage 
forms, the wider the drug loading range at which robust performance is 
assured for each API module, the greater the flexibility of the multidrug 
dosage form for individualized multidrug therapy. 
4.2. Importance of robust individual module dose and release 
performance at high drug loadings for individualized multidrug therapy 
A key driver for the existence of multidrug dosage forms is the pro-
motion of patient acceptability by reducing pill burdens and simplifying 
administration. In order to switch from the administration of multiple 
APIs via discrete dosage forms to a single combination dosage form of 
acceptable size, (Fig. 10), each API in the product should occupy a 
comparatively lower volume corresponding to its sub-dosage form 
module size. Yet, the API is still required to span its entire dose range. 
This is due to the size constraints of pharmaceutical dosage forms 
intended to be swallowed intact. 
Flexible multidrug dosage forms, which facilitate individualization, 
require an even higher degree of modularity than multidrug dosage 
forms with fixed dose, fixed release, or interdependent dose, release, and 
dosage form size. To achieve flexible dosing and/or flexible release for 
individualization, each API module in the dosage form requires recon-
figurable combinations of varying dose and drug release. The API is still 
required to span its entire clinical dose range despite the progressive 
reduction in module size in an eventual assembled dosage form for 
individualized multidrug therapy. Assuming a typical dosage form (e.g. 
a flat-faced cylindrical tablet with 4 mm height and 8 mm diameter 
corresponding to 200 mm3), the module size of 3.2 mm3 in this study 
Fig. 9. Product variety achievable through reconfiguration of unique modules across varying drug loading ranges showing that wide drug loading ranges are 
desirable to assure enhanced variety through reconfiguration. 
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would allow sixty-two modules to fit within the volumetric constraints 
of the dosage form, enabling future individualized multidrug therapy 
from a degree of modularity perspective. However, to access higher 
combined doses of APIs, it is essential to incorporate higher doses in 
smaller modules. 
Fig. 11 shows that the sixty-two modules that comprise a dosage 
form in this study can deliver approximately 100 mg of API (50% w/w 
modules contained 1800 µg API). 
This 100 mg represents the sum of doses of all constituent APIs in the 
multidrug dosage form. The corresponding fixed-dose combination 
products have the same maximum dose but the requirement for 
homogeneity at the maximum drug load is inherently stricter for 
modular dosage forms for individualized multidrug therapy due to 
smaller modules and an overall higher degree of modularity. This 
stricter requirement is to enable reproducible individual module dose 
and release performance for reconfiguration. Fig. 11 shows that, without 
incorporating higher drug loads within each module, delivering higher 
doses towards 1000 mg or more either requires an increased size of the 
multidrug dosage form or reverting to separate administrations. Neither 
promote patient acceptability, which is a key aspect of individualized 
therapy, alongside safety and effectiveness. This is true for single drug 
therapy but is exacerbated for multidrug therapy, even with current 
mass-produced pharmaceuticals on the market. The greater the number 
of APIs to be incorporated or the higher the doses of the constituent 
APIs, the higher the demand for robust performance at higher drug loads 
and smaller module sizes. 
4.3. Summary of requirements for extension of design window based on 
principal study outcomes 
In addition to obtaining robust and reproducible individual module 
dose and release performance at low and high drug loads and small 
module sizes, to exploit the advantage of the amorphous state for 
dissolution rate and bioavailability enhancement, promote clinical 
relevance, and promote wide applicability of multidrug dosage forms for 
individualized multidrug therapy, Fig. 12 summarizes the currently 
satisfied technical criteria for individualized multidrug therapy with 
poorly water-soluble APIs, based on the systems investigated in this 
study. 
Low variability in dose at low and high drug loads was achieved due 
to homogeneity in drug content and distribution and high precision in 
mass and dimensions of individual modules (down to 3.6 mg, 3.2 mm3 in 
this study). The former could be attributed mainly to the combined 
ability of the selected polymeric carrier and the selected melt extrusion 
processing parameters to completely solubilize the drug in the filament 
extrudate, resulting in a sufficiently homogeneous drug distribution 
along the filament at length scales corresponding to individual modules 
or smaller. Future translation to automated and scalable manufacturing 
technologies for module generation requires both homogeneous distri-
bution of the drug in the feedstock spanning a wide drug loading range 
as well as dispensing accuracy and precision for module fabrication. 
These are the same requirements for reproducible and robust dose and 
release performance for drugs with high aqueous solubility, so the cur-
rent design window also includes such drugs. Low drug loads in indi-
vidual modules define not only the range of the lower limit of the dose 
range but importantly, throughout the dose range they determine the 
minimum dose increment which can be used for fine tuning the dose to 
the needs of individual patients. In this study, at 5% w/w API and a 
module mass of 3.6 mg, this corresponded to a dose increment of 180 µg. 
Since drug loads lower than 5% w/w are not expected to adversely alter 
the homogeneity of drug distribution during melt extrusion (Llusa et al., 
2016; Park et al., 2013), it can be anticipated that even lower dose in-
crements towards placebo modules can be achieved in future. 
Dose individualization alone is insufficient for individualized ther-
apy, which requires simultaneous tailoring of all the attributes in a 
dosage form to individual patient needs (Govender et al., 2020a; 
Govender et al., 2020b). Consequently, a low variability in release ki-
netics was also demonstrated alongside accuracy and precision in dose 
at an individual module level at low and high drug loads. Notably, ho-
mogeneous distribution of the dose fraction within the module itself 
(thus at a smaller length scale than the module) is required for repro-
ducible release performance. Not only should this distribution be com-
parable between modules in the solid state but changes in drug 
distribution during hydration should also be consistent between mod-
ules. Translating this low variability in dose and release performance to 
robust, clinically relevant performance for poorly soluble APIs requires 
amorphization in the solid state and a maintained amorphous state 
Fig. 10. Design challenges for individualized multidrug therapy that formed 
the basis of this study involving transitions from discrete to combination dosage 
forms and from fixed to flexible combination dosage forms with multifunctional 
individualization. Axes are not to scale. 
Fig. 11. Degree of product modularity attainable for administration of indi-
vidualized multidrug therapy at different required doses. Axes are not to scale. 
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throughout dissolution (and in vivo uptake) to fully harness the benefits 
of the amorphous state in bioavailability enhancement and individual-
ization. Amorphization in the solid state was achieved for all composi-
tions due to process and polymer selection to generate amorphous solid 
dispersions. However, under non-sink conditions, the maintenance of 
the amorphous state throughout dissolution was only achieved for 
NAP5, which benefitted from the solubility advantage of the amorphous 
state and crystallization inhibition by the polymer, allowing supersat-
uration to be reached and maintained. In contrast, although FEL5 
amorphization allowed supersaturation to be achieved, incomplete drug 
release and the evolution of crystals from solution was attributed to the 
inability of the polymer (at the concentration use in this study) to sta-
bilize the dissolved FEL. Varying recrystallization tendencies of the APIs 
did not contribute to variability in dose fractions or drug release kinetics 
within individual modules across the investigated drug loading range of 
5% w/w to 50% w/w API, measured when 50 mM SDS was included in 
the dissolution medium. In this study, SDS was used to facilitate mea-
surement of variability in release kinetics between modules. For some 
drugs, SDS inclusion in the dissolution medium is recommended to 
improve performance and simulate certain in vivo conditions. However, 
in the specific case of individualized multidrug therapy, an API’s reli-
ance on SDS for optimal performance could influence the performance of 
other APIs intended to be included the multidrug dosage form. This 
could restrict the applicability of multidrug dosage forms further to 
systems that perform comparably with or without SDS e.g. NAP5 in this 
study. Crystallization in the solid state upon hydration (NAP50 and 
FEL50) and crystallization from solution (FEL5) emphasize that polymer 
selection for crystallization inhibition in the solid state and solution is a 
key determinant in extending the applicability of multidrug dosage 
forms towards individualized multidrug therapy with poorly water- 
soluble APIs. 
5. Conclusions 
Enabling individualized multidrug therapy with modular dosage 
forms is accompanied by stricter requirements on accuracy and preci-
sion of the dose and robustness in release kinetics due to the small size of 
modules in multidrug dosage forms for individualization. The demand 
for higher drug loads at smaller module sizes could impact drug distri-
bution, dose, and release kinetics. On the length scale of an individual 
module, this study has demonstrated that reproducible dose and release 
performance was achieved both at a wide drug loading range and at a 
small module size. This is critical to obtain the desired degree of 
modularity for individualization and for simplified administration of 
multidrug therapy as multidrug dosage forms upon future assembly of 
modules. 
This study expanded the current design window for poorly water- 
soluble drugs by demonstrating reproducible individual module dose 
and release performance with poorly water-soluble APIs with different 
physicochemical characteristics. This demonstration supports future 
assembly of modules into multidrug dosage forms for individualized 
multidrug therapy, where applicability to a broader range of APIs and 
interchangeability between APIs to suit diverse individual therapeutic 
regimens can be achieved. Regardless of drug load, API recrystallization 
tendency did not impact the attainment of accurate and precise dose 
fractions or reproducible release kinetics in 3.6 mg (~3.2 mm3) mod-
ules. In fact, despite the higher inherent recrystallization tendency of 
NAP, it exhibited superior performance to FEL at low drug loads due to 
amorphization and stabilization of the drug in solution by the polymer. 
Polymer selection was deemed to be of primary importance to expand-
ing the design window (over the dose and inherent recrystallization 
tendency of the API). 
Requirements for individualized multidrug therapy applicable to 
APIs with poor aqueous solubility complements the research trajectory 
in the field of amorphous solid dispersions with regards to the need for 
incorporation of higher drug loads with robust performance (Dedroog 
et al., 2019; Lu et al., 2019; Tian et al., 2020). For individualized ther-
apy, this performance should be assured at the size of the modules 
comprising a dosage form. Our study outcomes make a strong case in 
favour of interdisciplinary research for individual patient benefit to be 
maximized. Importantly, progress towards the goal of improved per-
formance at higher drug loads will not only improve dosage form per-
formance for conventional single drug therapy with poorly soluble APIs 
but also represents a key missing puzzle piece in realizing individualized 
multidrug therapy for a wider variety of APIs. 
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